More than 15,000 life sciences industry professionals will arrive in San Diego this month for the annual BIO International Convention. LSIPR looks at some of the most interesting sessions, and talks to a couple of speakers.
Acting against infringers can involve the pharmaceutical regulatory framework and civil law as well as following the more usual pathways, says José R. Trigueros.
Amended rules for food and drink packaging seek to ensure that people can easily identify the high calorific content of some of these products, as Daniel Sanchez and Victor Ramirez report.
The rate of development in the biotech sector means revisions to the patent guidelines are more needed than ever, says Marisa Moura Momoli.
The patent regulatory framework in Mexico needs to evolve if the investment in, and marketing of, promising biotechnology drug products is to succeed, says Hector E. Chagoya.
Obviousness-type double patenting is a serious consideration that patent owners should keep in mind during the examination of an application or in performing due diligence on a patent portfolio, says MaryAnne Armstrong.
The effect of obviousness-type double patenting on patent term extension and patent term adjustment in the biotech and pharma industry needs careful consideration, as Gaby L. Longsworth and Eric K. Steffe report.
The new examination guidelines do not carry the weight of law, and it is not likely that their more extreme aspects will withstand judicial scrutiny, but practitioners need to keep tabs on court decisions, says Courtenay C. Brinckerhoff.
With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications.
With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson.